Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

9 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Investigation of gene expression alterations of pancreatic cancer caused by Deferasirox administration

ABSTRACT: To investigate the genetic effect of Deferasirox in pancreatic cancer, we examined gene expression alternations in the removed tumors exposed to Deferasirox. Pancreatic cancer cells (BxPC-3) in culture were harvested and viable cells were injected subcutaneously into the backs of the mice. When tumor volumes reached 150 mm3, treatment began. The treatment group of mice received Deferasirox suspended in saline, which was administered by oral gavage every second day, with three treatments per week, over 21 days at concentrations of 200 mg/kg. The control mice were treated with the vehicle alone. At the end of the experiment, the mice were sacrificed and the tumors were excised and processed for genetic analyses. A total of 6 tumors were analyzed. Of these, 3 tumors were removed from vehicle-treated mice, and the other 3 tumors were removed from Deferasirox 200 mg/kg-treated mice.

ORGANISM(S): Homo sapiens

SUBMITTER: Hirofumi Harima

PROVIDER: E-GEOD-81363 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Global mRNA expression profiling of patient derived pancreatic carcinoma xenograft Bo63 following JQ1-SAHA combination therapy

Project description:Global mRNA expression profiling of patient derived pancreatic carcinoma xenograft Bo63 were collected using Agilent human whole genome array (G4845A AMADID 026652, cRNA 4x44k V2) . Two different sources of RNA were analyzed: 1.) Bo63 xenograft tumors grown on nude mice treated with vehicle only as control. 2.) Bo63 xenograft tumor grown on nude mice treated with JQ1 and SAHA (SAHA 25 mg/kg 1-0-0 and JQ1 50 mg/kg 0-0-1, treatment was imitated when tumor size reached 200 mm³ +/- 20 mm³. Two conditions (vehicle vs JQ1-SAHA treatment), each condition is represented by 3-4 biological replicates

2015-09-20 | E-GEOD-64837 | biostudies-arrayexpress

Global mRNA expression profiling of patient derived pancreatic carcinoma xenograft Bo63 following JQ1-SAHA combination therapy

2015-09-20 | GSE64837 | GEO

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [OV5398PDX RNAseq]

Project description:We performed RNA sequencing on tumors harvested from OV5398 (ovarian) PDX treated for 40-50 days with either control vehicle (PEG), 100 mg/kg BID INX-315 or 200 mg/kg QD INX315.

2023-11-22 | GSE243151 | GEO

Phosphotyrosine profiling of in vivo signaling changes in erlotinib-treated glioblastoma flank xenografts

Project description:Mass spectrometry-based quantitative proteomics profiling of in vivo signaling changes in 16 GMB xenograft tumors treated with vehicle and erlotinib (5 mg/kg, 33 mg/kg, 100 mg/kg).

2018-11-06 | PXD006769 | Pride

Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models (II)

Project description:Analysis of the transcriptome of allografted mouse tumors after treatment with rapamycin and PD0325901. Nkx3.1CreERT2/+; Ptenflox/flox; KrasLSL-G12D/+ (NPK mice) were induced and their tumors removed to generate allograft lines by implanting a 1.5 mm3 tumor fragment in the subcutaneous space of athymic nude mice. Allografted NPK tumors were allowed to grow until they reached a volume of 1 cm3, at which moment they were randomly assigned to either vehicle (Veh) or combination therapy using rapamycin and PD0325901 (RAPPD). Allografted mice were administered rapamycin (10 mg/kg) and PD0325901 (10 mg/kg) during five consecutive days (Allo SHORT). Mice were euthanized in the fifth day 6 hours after having received the last treatment and the tumors were harvested and snap frozen for subsequent molecular analysis.

2015-09-17 | GSE69213 | GEO

Gene expression profiling of HhAntag-treated pancreatic xenografts

Project description:Four vehicle-treated and four HhAntag-treated pancreatic xenograft tumors were profiled for gene expression changes using Affymetrix U133 Plus 2.0 and Affymetrix Mouse Genome 430 2.0 arrays. Keywords: comparative gene expression, hedgehog, hh A primary human pancreatic tumor xenograft (1051178-A) was established by direct implantation of surgical material into female CD1 nu/nu mice of 6-8 weeks of age. Tumors were serially passaged into larger cohorts of mice for efficacy testing and subsequently distributed into tumor volume-matched cohorts upon tumors reaching between 200 to 350 mm3. HhAntag was resuspended in 0.5% methyl-cellulose, 0.2% Tween-80 (MCT) and administered orally twice daily at 75 mg/kg from a 10 mg/ml suspension. MCT alone served as vehicle control. Tumor xenografts (4/group) were excised following 21 days of dosing and RNA was extracted. Preparation of complementary RNA, Human Genome U133 Plus 2.0 array and Mouse Genome 430 2.0 array hybridizations, and subsequent data analysis were carried out using Affymetrix protocols, with signal intensities being determined by the MAS5.0 algorithm.

2008-09-12 | E-GEOD-11981 | biostudies-arrayexpress

Predicting drug response in human prostate cancer from preclinical analysis of in vivo mouse models (II)

2015-09-17 | E-GEOD-69213 | biostudies-arrayexpress

proteome and pathway effects of chronic haoperidol treatment in mouse hippocampus

Project description:Seven male C57BL/6 mice, at 10 weeks of age, were injected daily intraperitoneally with 0.5 mg/kg of haloperidol, for 28 days. A control group of six animals was injected with vehicle only (saline).

2015-11-30 | PXD002250 | Pride

Collagen induced arthritis plasma proteomic analysis

Project description:The aim of the project is to analyze the plasma proteomic profile of an animal model of arthritis (Collagen Induced Arthritis; CIA) in response to different treatments. For this, plasma samples from mice under five different treatments were analyzed (N=6 per group): Vehicle, CIA, CIA + Δ9-THCA-A (20 mg / kg), CIA + Δ9-THCA-A (20 mg / kg) + T0070907 (5 mg / kg) and CIA + Δ9-THCA-A (20 mg / kg) + SR141716A (5 mg / kg).

2020-09-18 | PXD015274 | Pride

Effect of MetAP2 the inhibitor SDX-7320 on gene expression in BT-474 xenografts

Project description:Analysis of gene expression using bulk RNASeq was performed on tumors dissected from vehicle-treated and SDX-7320-treated mice (12 mg/kg). The analysis of RNASeq data showed that a several pathways were modulated in tumors from mice treated with SDX-7320.

2024-03-29 | GSE230687 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data